CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors

Purpose. To study radiological response to stereotactic radiotherapy for focal liver tumors. Materials and Methods. In this IRB-approved, HIPAA-compliant study CTs of 68 consecutive patients who underwent stereotactic radiotherapy for liver tumors between 01/2006 and 01/2010 were retrospectively re...

Full description

Bibliographic Details
Main Authors:	Brook, Olga R., Thornton, Eavan, Mendiratta-Lala, Mishal, Mahadevan, Anand, Raptopoulos, Vassilious, Brook, Alexander, Najarian, Robert, Sheiman, Robert, Siewert, Bettina
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499630/

id	pubmed-4499630
recordtype	oai_dc
spelling	pubmed-44996302015-07-28 CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors Brook, Olga R. Thornton, Eavan Mendiratta-Lala, Mishal Mahadevan, Anand Raptopoulos, Vassilious Brook, Alexander Najarian, Robert Sheiman, Robert Siewert, Bettina Research Article Purpose. To study radiological response to stereotactic radiotherapy for focal liver tumors. Materials and Methods. In this IRB-approved, HIPAA-compliant study CTs of 68 consecutive patients who underwent stereotactic radiotherapy for liver tumors between 01/2006 and 01/2010 were retrospectively reviewed. Two independent reviewers evaluated lesion volume and enhancement pattern of the lesion and of juxtaposed liver parenchyma. Results. 36 subjects with hepatocellular carcinoma (HCC), 25 with liver metastases, and seven with cholangiocarcinoma (CCC) were included in study. Mean follow-up time was 5.6 ± 7.1 months for HCC, 6.4 ± 5.1 months for metastases, and 10.1 ± 4.8 months for the CCC. Complete response was seen in 4/36 (11.1%) HCCs and 1/25 (4%) metastases. Partial response (>30% decrease in long diameter) was seen in 25/36 (69%) HCCs, 14/25 (58%) metastases, and 7/7 (100%) of CCCs. Partial response followed by local recurrence (>20% increase in long diameter from nadir) occurred in 2/36 (6%) HCCs and 4/25 (17%) metastases. Liver parenchyma adjacent to the lesion demonstrated a prominent halo of delayed enhancement in 27/36 (78%) of HCCs, 19/21 (91%) of metastases, and 7/7 (100%) of CCCs. Conclusion. Sustainable radiological partial response to stereotactic radiotherapy is most frequent outcome seen in liver lesions. Prominent halo of delayed enhancement of the adjacent liver is frequent finding. Hindawi Publishing Corporation 2015 2015-06-29 /pmc/articles/PMC4499630/ /pubmed/26221135 http://dx.doi.org/10.1155/2015/126245 Text en Copyright © 2015 Olga R. Brook et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Brook, Olga R. Thornton, Eavan Mendiratta-Lala, Mishal Mahadevan, Anand Raptopoulos, Vassilious Brook, Alexander Najarian, Robert Sheiman, Robert Siewert, Bettina
spellingShingle	Brook, Olga R. Thornton, Eavan Mendiratta-Lala, Mishal Mahadevan, Anand Raptopoulos, Vassilious Brook, Alexander Najarian, Robert Sheiman, Robert Siewert, Bettina CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors
author_facet	Brook, Olga R. Thornton, Eavan Mendiratta-Lala, Mishal Mahadevan, Anand Raptopoulos, Vassilious Brook, Alexander Najarian, Robert Sheiman, Robert Siewert, Bettina
author_sort	Brook, Olga R.
title	CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors
title_short	CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors
title_full	CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors
title_fullStr	CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors
title_full_unstemmed	CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors
title_sort	ct imaging findings after stereotactic radiotherapy for liver tumors
description	Purpose. To study radiological response to stereotactic radiotherapy for focal liver tumors. Materials and Methods. In this IRB-approved, HIPAA-compliant study CTs of 68 consecutive patients who underwent stereotactic radiotherapy for liver tumors between 01/2006 and 01/2010 were retrospectively reviewed. Two independent reviewers evaluated lesion volume and enhancement pattern of the lesion and of juxtaposed liver parenchyma. Results. 36 subjects with hepatocellular carcinoma (HCC), 25 with liver metastases, and seven with cholangiocarcinoma (CCC) were included in study. Mean follow-up time was 5.6 ± 7.1 months for HCC, 6.4 ± 5.1 months for metastases, and 10.1 ± 4.8 months for the CCC. Complete response was seen in 4/36 (11.1%) HCCs and 1/25 (4%) metastases. Partial response (>30% decrease in long diameter) was seen in 25/36 (69%) HCCs, 14/25 (58%) metastases, and 7/7 (100%) of CCCs. Partial response followed by local recurrence (>20% increase in long diameter from nadir) occurred in 2/36 (6%) HCCs and 4/25 (17%) metastases. Liver parenchyma adjacent to the lesion demonstrated a prominent halo of delayed enhancement in 27/36 (78%) of HCCs, 19/21 (91%) of metastases, and 7/7 (100%) of CCCs. Conclusion. Sustainable radiological partial response to stereotactic radiotherapy is most frequent outcome seen in liver lesions. Prominent halo of delayed enhancement of the adjacent liver is frequent finding.
publisher	Hindawi Publishing Corporation
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499630/
_version_	1613246962783485952

CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors

Similar Items